4 questions about legal & regulatory.
It's complicated and the answer keeps changing. FDA-approved peptides (semaglutide, tirzepatide, PT-141) are fully legal with a prescription. Research peptides sold "for research purposes only" exist in a grey zone — buying them isn't illegal, but marketing them for human use is. Everyone knows what's happening. Nobody says it out loud. As of February 2026, the RFK reclassification moved a bunch of previously restricted peptides (BPC-157, TB-500, CJC-1295, Ipamorelin, GHK-Cu, and others) back to Category 1, meaning compounding pharmacies can prepare them with a prescription again. The rules are actively shifting — what was restricted last year might not be today.
Category 1 = compounding pharmacies can make it with a prescription. Category 2 = they can't. Essentially a compounding ban. In 2024, the FDA put 19 peptides on Category 2, including BPC-157 and TB-500. In February 2026, about 14 of those were announced to move back to Category 1. Five are still restricted: Melanotan II, GHRP-2, GHRP-6, LL-37, and PEG-MGF. If a peptide you're interested in was recently restricted and you're not sure where it stands now, check the current list — it's been a moving target.
On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced that roughly 14 of 19 peptides on the FDA's Category 2 restricted list would move back to Category 1. That means licensed compounding pharmacies can legally prepare them again with a valid prescription. The list includes BPC-157, TB-500, Thymosin Alpha-1, CJC-1295, Ipamorelin, AOD-9604, GHK-Cu, Selank, Semax, KPV, and MOTS-C. Important distinction: this doesn't mean FDA approval. It means compounding is permitted. The formal PCAC review was scheduled for July 2026.
Peptides sold online labeled "for research purposes only" or "not for human consumption" are sidestepping FDA regulation by not marketing for human use. You're technically buying for "research." In practice, everyone knows what's going on. The risks are real though: no FDA quality oversight, no guaranteed purity or sterility, wildly inconsistent quality between vendors, and zero legal protection if something goes wrong. The RFK reclassification is making this loophole less necessary — compounding pharmacies can now prepare many of these peptides with proper prescriptions and actual quality controls. If you have the option to go the prescription route, it's worth the extra cost.
← All FAQ topics | Browse all peptides
vialprep research · Sources: PubMed, FDA, peer-reviewed trials · How we verify